Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) issued an update on its FY17 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $5.40-5.55 for the period, compared to the Thomson Reuters consensus estimate of $5.33. The company issued revenue guidance of $3.45-3.53 billion, compared to the consensus revenue estimate of $3.47 billion.

Alexion Pharmaceuticals, Inc. (ALXN) traded up 3.80% during mid-day trading on Thursday, hitting $136.05. 2,380,593 shares of the company were exchanged. The company has a market cap of $30.55 billion, a price-to-earnings ratio of 64.82 and a beta of 1.39. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $145.41. The stock’s 50 day moving average is $121.46 and its 200-day moving average is $122.77.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.25 by $0.31. The company had revenue of $912 million during the quarter, compared to analysts’ expectations of $846.15 million. Alexion Pharmaceuticals had a return on equity of 11.72% and a net margin of 14.52%. The business’s revenue was up 21.1% on a year-over-year basis. During the same period last year, the business earned $1.13 earnings per share. Equities research analysts predict that Alexion Pharmaceuticals, Inc. will post $5.33 EPS for the current year.

A number of research analysts have issued reports on ALXN shares. Morgan Stanley raised Alexion Pharmaceuticals from an equal weight rating to an overweight rating and lifted their price objective for the company from $101.08 to $138.00 in a report on Thursday, May 25th. Barclays PLC reissued an overweight rating and set a $155.00 price objective on shares of Alexion Pharmaceuticals in a report on Tuesday, May 9th. Cowen and Company reissued an outperform rating and set a $180.00 price objective on shares of Alexion Pharmaceuticals in a report on Friday, April 28th. J P Morgan Chase & Co cut Alexion Pharmaceuticals from an overweight rating to a neutral rating in a report on Tuesday, May 23rd. Finally, Zacks Investment Research raised Alexion Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, April 18th. Seven research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of Buy and an average target price of $156.62.

In related news, Director Bros. Advisors Lp Baker bought 660,779 shares of the firm’s stock in a transaction dated Thursday, June 15th. The stock was bought at an average cost of $117.33 per share, for a total transaction of $77,529,200.07. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Ludwig Hantson bought 10,000 shares of the firm’s stock in a transaction dated Wednesday, June 14th. The shares were bought at an average price of $116.72 per share, with a total value of $1,167,200.00. Following the completion of the transaction, the chief executive officer now directly owns 38,725 shares in the company, valued at approximately $4,519,982. The disclosure for this purchase can be found here. Insiders have bought a total of 2,019,734 shares of company stock valued at $235,606,846 over the last 90 days. Corporate insiders own 4.35% of the company’s stock.

WARNING: “Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Releases FY17 Earnings Guidance” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.